Clinical value of recombinant human adenovirus type 5 in transarterial chemoembolization in patients with cervical cancer.

ZHANG Ping; CHEN Long; ZHANG Wei-na; ZHANG Sheng-miao.

doi:10.7504/fk2015040117

Chinese Journal of Practical Gynecology and Obstetrics ›› 2015, Vol. 31 ›› Issue (5) : 453-457. DOI: 10.7504/fk2015040117

ZHANG Ping, CHEN Long, ZHANG Wei-na, ZHANG Sheng-miao.

Author information +

History +

Abstract

Abstract： Objective To evaluate the clinical value of recombinant human adenovirus type 5 in transarterial chemoembolization in patients with cervical cancer. Methods A total of 92 patients with cervical cancer (ⅠB2-ⅡB) from June 2008 to December 2014 were divided into two groups. Experimental group (47 patients) received recombinant human adenovirus type 5 and transarterial chemoembolization，while the control group (45 patients) received transarterial chemoembolization only.Totally 84 cases received operation therapy after 3-4 weeks. The tumor size, levels of SCC-Ag and HR-HPV，operation situation, postoperative pathology and toxicity of the two groups were compared respectively. Results Compared with control group（84.44％）, the tumor regression rate of the experimental group(89.36％) had no significant difference（χ2=0.49,P=0.484）;there was no significant difference (χ2=2.31,P=0.128) between experimental group(78.72％) and control group(64.44％) in terms of the decreased level of SCC-Ag;the expression level decrease of HR-HPV in experimental group(57.45％) was significantly more than that of the control group(28.89％) (χ2=7.63，P=0.006). Blood lose（t=3.57,P<0.001）and vascular tumors bolt(χ2=7.11,P=0.008) decreased significantly, but the total positive rate of lymph nodes(χ2=0.70,P=0.404), parametrium invasion (χ2=1.74,P=0.188) and parametrial infiltration (χ2=1.30,P=0.254) had no significant difference between the two groups. The incidence of the high fever had significant difference（χ2=9.21，P=0.002）. Conclusions In the treatment of transarterial chemoembolization for the cervical cancer, recombinant human adenovirus type 5 can be beneficial to the operation and reinforce the treatment effect, and do not increase the adverse reaction rate. It is a treatment method worthy of being explored in the research field of cervical cancer.

Key words

cervical cancer / transarterial chemoembolization / recombinant human adenovirus type 5

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

ZHANG Ping, CHEN Long, ZHANG Wei-na, ZHANG Sheng-miao.. Clinical value of recombinant human adenovirus type 5 in transarterial chemoembolization in patients with cervical cancer.[J]. Chinese Journal of Practical Gynecology and Obstetrics. 2015, 31(5): 453-457 https://doi.org/10.7504/fk2015040117

References

［1］   Dong J, Li W, Dong AN, et al. Gene therapy for unresectable hepatocellular carcinoma using recombinant human adenovirus type 5 ［J］. Med Oncol, 2014, 31(95):1-8.

［2］   陈春林，刘萍.妇产科放射介入治疗学［M］.北京：人民卫生出版社，2003:266.

［3］    杨帆，胡斌，胡春燕，等.胸腔内注射重组人5型腺病毒治疗晚期肺癌恶性胸腔积液的疗效观察［J］.实用医学杂志，2013,29（17）：2885-2886.

［4］    周立，何婉婉，朱桢楠，等.溶瘤腺病毒靶向癌症治疗的临床研究进展［J］.中国生物工程杂志，2013,33（12)：105-113.

［5］    Sviatheko VA, Tarasova MV, Netesov SV, et al. Oncolytic adenovirus in anti-cancer therapy: current status and perspective[J]. 2012, 46(4):556-569.

［6］    Dong J, Li W, Dong A, et al. Gene therapy for unresectable hepatocellular carcinoma using recombinant human adenovirus type 5 ［J］. Med Oncol, 2014, 31(8):95-102.

［7］    李玉，李文刚，张素静.重组人5型腺病毒注射液介入途径给药治疗恶性肿瘤的安全性研究［J］. 上海医药，2013，34（1）：24-26.

［8］    Ma G, Kawamura K, Li Q, et al. Combinatory cytotoxic effects produced by E1B 55 kDa deleted adenoviruses and chemotherapeutic agents are dependent on the agents in esophageal carcinoma ［J］. Cancer Gene Therapy, 2010, 17(11):803-813.

［9］    韩志刚, 张国福,谢洁林，等. Ⅰb2～Ⅱa期宫颈癌根治性子宫切除术前子宫动脉栓塞化疗及髂内动脉前干支化疗的疗效比较［J］. 介入放射学杂志, 2010，19(12): 954-957.

［10］    何玉, 王才智,张阳, 等.子宫动脉灌注栓塞化疗在早期巨块型宫颈癌中的应用研究［J］. 实用医学杂志, 2011,27(16): 2983-2985.

［11］    Wei H,Wang N,Zhang Y, et al. Clinical significance of Wnt-11 and squamous cell carcinoma antigen expression in cervical cancer［J］. Med Oncol, 2014，31(5): 933.

［12］    Yin Q,Wang Y,Zhang C, et al. Effects of two genes coding squamous cell carcinoma antigen on the diagnosis and treatment of cervical squamous cell carcinoma［J］.Pak J Med Sci, 2014，30(2): 282-286.

［13］    Jea H, Mikyung K, Yong TJ, et al. Human papillomavirus vaccine: widening the scope for cancer prevention［J］. Mol Carcinol,2011,50(4):244-255.

［14］    Li G，He L, Zhang E, et al. Overexpression of human papilloma virus (HPV) type 16 oncoproteins promotes angiogenesis via enhancing HIF-1α and VEGF expression in non- small cell lung cancer cells［J］. Cancer Lett, 2011,311( 2): 160-170.

［15］    徐勤，刘丽萍，杨丽华，等.HPV病毒负荷量与血清VEGF预测宫颈癌新辅助化疗效果   的价值探讨［J］.现代妇产科进展，2013,22(1):45-47.

［16］    侯宾，崔珂钒，蒋力.重组人5型腺病毒术中浸润注射食管癌22例［J］.中国药业，2012,21（5）：89.

（2014-12-10来稿    2015-02-05修回）